Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3

Biochemical Pharmacology

Volumn 74, Issue 1, 2007, Pages 161-168

  Uwai, Yuichi ^a   Motohashi, Hideyuki ^a   Tsuji, Yoshie ^a   Ueo, Harumasa ^a   Katsura, Toshiya ^a   Inui, Ken ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Drug interaction; Mycophenolic acid; Mycophenolic acid glucuronide; Organic anion transporter; Tubular secretion

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; AZATHIOPRINE; CARRIER PROTEIN; CYCLOSPORIN A; DIMETHYL SULFOXIDE; ESTRONE SULFATE; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORGANIC ANION TRANSPORTER HOAT1; ORGANIC TRANSPORTER ANION TRANSPORTER HOAT3; PROBENECID; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; DRUG ELIMINATION; DRUG STRUCTURE; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CLEARANCE; KIDNEY TUBULE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TRANSPORT;

BIOLOGICAL TRANSPORT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; KIDNEY; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; TIME FACTORS;

EID: 34249014286     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.024     Document Type: Article

References (32)

1. Bullingham R., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
2. Picard N., Ratanasavanh D., Prémaud A., Le Meur Y., and Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33 (2005) 139-146
3. Bernard O., and Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32 (2004) 775-778
4. Girard H., Court M.H., Bernard O., Fortier L.C., Villeneuve L., Hao Q., et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14 (2004) 501-515
5. Gimenez F., Foeillet E., Bourdon O., Weller S., Garret C., Bidault R., et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 43 (2004) 685-692
6. Hesselink D.A., van Hest R.M., Mathot R.A., Bonthuis F., Weimar W., de Bruin R.W., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987-994
7. Cattaneo D., Perico N., Gaspari F., Gotti E., and Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62 (2002) 1060-1067
8. Vietri M., Pietrabissa A., Mosca F., and Pacifici G.M. Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 56 (2000) 659-664
9. Miyazaki H., Sekine T., and Endou H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol Sci 25 (2004) 654-662
10. Sweet D.H. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204 (2005) 198-215
11. Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13 (2002) 866-874
12. Uwai Y., Taniguchi R., Motohashi H., Saito H., Okuda M., and Inui K. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 19 (2004) 369-374
13. Ueo H., Motohashi H., Katsura T., and Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 70 (2005) 1104-1113
14. Page II R.L., Miller G.G., and Lindenfeld J. Drug therapy in the heart transplant recipient-part IV: drug-drug interactions. Circulation 111 (2005) 230-239
15. Laskin O.L. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 8 (1983) 187-201
16. Takeda M., Khamdang S., Narikawa S., Kimura H., Kobayashi Y., Yamamoto T., et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300 (2002) 918-924
17. Shitara Y., Horie T., and Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27 (2006) 425-446
18. Bullingham R., Monroe S., Nicholls A., and Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 (1996) 315-324
19. Nowak I., and Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41 (1995) 1011-1017
20. Mudge D.W., Atcheson B.A., Taylor P.J., Pillans P.I., and Johnson D.W. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit 26 (2004) 453-455
21. Johnson H.J., Swan S.K., Heim-Duthoy K.L., Nicholls A.J., Tsina I., and Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 63 (1998) 512-518
22. Kaplan B., Meier-Kriesche H., Friedman G., Mulgaonkar S., Gruber S., Korecka M., et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 39 (1999) 715-720
23. Uwai Y., Okuda M., Takami K., Hashimoto Y., and Inui K. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. Fed Eur Biochem Soc Lett 438 (1998) 321-324
24. Uwai Y., Saito H., Hashimoto Y., and Inui K. Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol 398 (2000) 193-197
25. Mulato A.S., Ho E.S., and Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 295 (2000) 10-15
26. Royer B., Zanetta G., Bérard M., Davani S., Tanter Y., Rifle G., et al. A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil. Clin Transplant 17 (2003) 158-161
27. Sakurai Y., Motohashi H., Ueo H., Masuda S., Saito H., Okuda M., et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res 21 (2004) 61-67
28. Sakurai Y., Motohashi H., Ogasawara K., Terada T., Masuda S., Katsura T., et al. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res 22 (2005) 2016-2022
29. Alak A.M. Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. Ther Drug Monit 19 (1997) 338-351
30. Christians U., and Sewing K.F. Cyclosporin metabolism in transplant patients. Pharmacol Ther 57 (1993) 291-345
31. Chan G.L., Erdmann G.R., Gruber S.A., Matas A.J., and Canafax D.M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 30 (1990) 358-363
32. Motohashi H., Uwai Y., Hiramoto K., Okuda M., and Inui K. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol 503 (2004) 25-30